Aktienanalyse zu CytomX Therapeutics Inc (CTMX)CTMXCytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CytomX Therapeutics Inc is not a good buy right now. The current price is $2.28, which is significantly below the average analyst price target of $11 to $14, indicating potential upside. However, the stock has seen a staggering 46.35% year-to-date decline and a 92.4% year-over-year revenue drop to $1.42 million, which raises serious concerns about its financial health. The RSI is at 33.876, indicating oversold conditions, but the overall negative sentiment from recent earnings misses and cash reserve declines suggests caution. The main risk is the company's substantial revenue decline and ongoing losses, as evidenced by a net income of -$20.67 million in Q2 2026, which could further impact investor confidence and stock performance.

7 analysts cover CTMX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 9.00.